Immune privilege: A recurrent theme in immunoregulation?

Immunological Reviews

Volumn 213, Issue 1, 2006, Pages 5-11

  Mellor, Andrew L ^a   Munn, David H ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Immune privilege; Immunity; Regulation; Tolerance

Indexed keywords

ANTIBODY; ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HLA G ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INDOLEAMINE 2,3 DIOXYGENASE; UNCLASSIFIED DRUG;

ALLOGRAFT; ANATOMICAL VARIATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELLULAR IMMUNITY; DENDRITIC CELL; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 33748744234     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00443.x     Document Type: Review

References (48)

1. Simpson E. A historical perspective on immunological privilege. Immunol Rev 2006;213:12-22.
2. Caspi RR. Ocular autoimmunity: the price of privilege? Immunol Rev 2006;213:23-35.
3. Hunt JS. Stranger in a strange land. Immunol Rev 2006;213:36-47.
4. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
5. Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev 2006;213:66-81.
6. Crispe IN, Giannandrea M, Klein I, John B, Sampson B, Wuensch S. Cellular and molecular mechanisms of liver tolerance. Immunol Rev 2006;213:101-118.
7. Iweala OI, Nagler CR. Immune privilege in the gut: the establishment and maintenance of nonresponsiveness to dietary antigens and commensal flora. Immunol Rev 2006;213:82-100.
8. Kraal G, Samsom JN, Mebius RE. The importance of regional lymph nodes for mucosal tolerance. Immunol Rev 2006;213:119-130.
9. Gajewski TF, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-145.
10. Munn DH, Mellor AL. The tumor-draining lymph node as an immune-priviliged site. Immunol Rev 2006;213:146-158.
11. Peters N, Sacks D. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev 2006;213:159-179.
12. Persidsky Y, Poluektova L. Immune privilege and HIV-1 persistence in the CNS. Immunol Rev 2006;213:180-194.
13. Mrass P, Weninger W. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 2006;213:195-212.
14. Wahl SM, Wen J, Moutsopoulos N. TGF-β: a mobile purveyor of immune privilege. Immunol Rev 2006;213:213-227.
15. Ferguson TA, Griffith TS. A vision of cell death: FasL and immune privilege 10 years later. Immunol Rev 2006;213:228-238.
16. Cobbold SP, et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006;213:239-255.
17. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science 1995;270:630-633.
18. Setiady YY, et al. Physiological self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+CD25+ regulatory T cells. Blood 2006;107:1056-1062.
19. Mellor AL, Munn DH. IDO expression in dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-774.
20. Guleria I, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005;202:231-237.
21. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5:266-271.
22. Mellor AL, Munn D. Policing pregnancy: Tregs help keep the peace. Trends Immunol 2004;25:563-565.
23. Munn DH, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-1193.
24. Mellor AL, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001;2:64-68.
25. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 2004;61:67-77.
26. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
27. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-213.
28. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006;24:209-226.
29. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
30. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
31. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;206:232-259.
32. Andersson J, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005;174:3143-3147.
33. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 2006;203:777-788.
34. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001;1:126-134.
35. Mahnke K, Knop J, Enk AH. Induction of tolerogenic DCs: 'you are what you eat'. Trends Immunol 2003;24:646-651.
36. Moser M. Dendritic cells in immunity and tolerance - do they display opposite functions? Immunity 2003;19:5-8.
37. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004;4:24-34.
38. Hawiger D, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-779.
39. Legge KL, et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 2002;196:217-227.
40. Rauh MJ, et al. SHIP represses the generation of alternatively activated macrophages. Immunity 2005;23:361-374.
41. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-346.
42. Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 2003;108:481-492.
43. Annacker O, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005;202:1051-1061.
44. Fallarino F, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752-6761.
45. Shapiro AM, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-238.
46. Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 2003;5:270-277.
47. Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs 2002;3:1590-1595.
48. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006;24:233-238.